PHARMACY

Forest, Merz to sue generic companies over Namenda patents

BY Drew Buono

NEW YORK Forest Laboratories and Merz have announced that they are suing several generic drug manufacturers, alleging patent infringements on the Alzheimer’s disease drug Namenda, according to the Associated Press.

The suits, which were filed in the U.S. District Court for the District of Delaware were filed against, Barr Laboratories, Cobalt Laboratories, Lupin, Orchid Chemicals & Pharmaceuticals, Teva Pharmaceuticals USA , Upsher-Smith Laboratories and Wockhardt.

Forest claims its patent for Namenda does not expire until April 2010, and that it is seeking patent extension approval through September 2013. Namenda generated sales of $192.9 million during the second quarter of fiscal 2008.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Taro settles patent suit, launches generic Trileptal

BY DSN STAFF

HAWTHORNE Taro announced Wednesday that it has settled a patent lawsuit with Novartis and will launch oxcarbazepine tablets, the generic version of Novartis’ Trileptal. Oxcarbazepine tablets are indicated to treat seizures.

The litigation with Novartis centered on Taro’s Paragraph IV certification challenging Novartis’ patent protection on Trileptal. On Nov. 15, 2007, Taro received Food and Drug Administration approval for its abbreviated new drug application for oxcarbazepine tablets in 150 mg, 300 mg and 600 mg strengths, but the company waited to launch the drug until the lawsuit was settled.

According to Taro, Trileptal currently has annual U.S. sales of approximately $700 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Sciele to launch six medications in 2008

BY DSN STAFF

ATLANTA In addition to Sciele’s announcement last week, reported in Drug Store News, that it will launch its new Sular formulation during the first quarter of 2008, the company also announced plans to launch five other drugs this year:

  • two new dosages of fenofibrate for the treatment of mixed dyslipidemia
  • Prandin for Type 2 diabetes
  • PrandiMet for Type 2 diabetes (pending FDA approval)
  • a head lice asphyxiation product (pending FDA approval)
  • a women’s health product

Sciele reaffirmed its full-year guidance at the JPMorgan 26th Annual Health Care Conference yesterday. As previously announced, full-year 2007 revenue is expected to range between $375 million and $385 million. The company expects full-year 2008 revenues to range from $440 million to $455 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?